<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02657447</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT: 2013-003908-39</org_study_id>
    <nct_id>NCT02657447</nct_id>
  </id_info>
  <brief_title>Dosimetry Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-02)</brief_title>
  <official_title>A Phase 1, Open Label, Randomized Study to Assess Pharmacokinetics, Biodistribution and Radiation Dosimetry of Lutetium (177Lu) Lilotomab Satetraxetan (Betalutin®) Radioimmunotherapy in Patients With Relapsed Non-Hodgkin Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nordic Nanovector</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nordic Nanovector</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a phase I, open label, randomized study to assess pharmacokinetics,&#xD;
      biodistribution and radiation dosimetry of lutetium (177Lu) lilotomab satetraxetan&#xD;
      (Betalutin®) radioimmunotherapy in patients with relapsed non-Hodgkin lymphoma. The study&#xD;
      will also investigate the safety, toxicity and efficacy of Betalutin and pre-dosing.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study is no longer relevant&#xD;
  </why_stopped>
  <start_date type="Actual">December 19, 2017</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dosimetry</measure>
    <time_frame>3 weeks</time_frame>
    <description>Estimation of individual tumour/organ uptake and retention of radioactivity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of participants with adverse events as assessed by NCTCAE.</measure>
    <time_frame>12 weeks</time_frame>
    <description>Adverse events by treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy (Best overall response rate)</measure>
    <time_frame>3 months - 1 year</time_frame>
    <description>Best overall response rate by treatment group as measured by Cheson Criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lilotomab pharmacokinetics</measure>
    <time_frame>3 weeks</time_frame>
    <description>Estimation using decay correction measurements</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Non-Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Arm 1: Betalutin with lilotomab dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Betalutin 15 MBq/kg b.w. with lilotomab pre-dosing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: Betalutin with lilotomab dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Betalutin 15MBq/kg b.w. with lilotomab pre-dosing</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Betalutin with lilotomab dose 1</intervention_name>
    <description>15 MBq/kg b.w. Betalutin (lutetium (177Lu) lilotomab satetraxetan) single injection, with lilotomab pre-dosing, dose 1</description>
    <arm_group_label>Arm 1: Betalutin with lilotomab dose 1</arm_group_label>
    <other_name>Betalutin</other_name>
    <other_name>Lymrit 37-02</other_name>
    <other_name>lutetium (177Lu) lilotomab satetraxetan</other_name>
    <other_name>HH1</other_name>
    <other_name>177Lu-DOTA-HH1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Betalutin with lilotomab dose 2</intervention_name>
    <description>15 MBq/kg b.w. Betalutin (lutetium (177Lu) lilotomab satetraxetan) single injection, with lilotomab pre-dosing, dose 2</description>
    <arm_group_label>Arm 2: Betalutin with lilotomab dose 2</arm_group_label>
    <other_name>Betalutin</other_name>
    <other_name>Lymrit 37-02</other_name>
    <other_name>lutetium (177Lu) lilotomab satetraxetan</other_name>
    <other_name>HH1</other_name>
    <other_name>177Lu-DOTA-HH1</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed (by WHO classification) relapsed indolent non-Hodgkin B-cell&#xD;
             lymphoma of following subtypes: Follicular lymphoma (follicular grade I-IIIA),&#xD;
             Marginal zone lymphoma (exclusion of MZL if large lymphocytes &gt; 50%), Small&#xD;
             lymphocytic lymphoma, Lymphoplasmacytoid and classical mantle cell lymphoma (no&#xD;
             blastoid MCL).&#xD;
&#xD;
          2. Requiring initiation of treatment for the NHL.&#xD;
&#xD;
          3. Relapsed after at least one line of therapy including rituximab combination&#xD;
             chemotherapy regimen.&#xD;
&#xD;
          4. Exhausted and/or ineligible for all standard treatment options.&#xD;
&#xD;
          5. Not a candidate for an autologous or allogeneic stem cell transplantation. Patients in&#xD;
             progression after successful stem cell collection before before high-dose therapy and&#xD;
             autologous stem cell transplantation may be considered for enrolment.&#xD;
&#xD;
          6. Age ≥ 18 years..&#xD;
&#xD;
          7. A pre-study ECOG performance status of 0-2. In selected patients an ECOG score of 3&#xD;
             can be acceptable if it is clearly lymphoma-associated at the discretion of the&#xD;
             investigator.&#xD;
&#xD;
          8. Life expectancy should be ≥ 3 months.&#xD;
&#xD;
          9. 9. &lt; 25% tumour cells in bone marrow biopsy prior to lilotomab/Betalutin treatment&#xD;
             (biopsy taken from a site not previously irradiated).&#xD;
&#xD;
         10. All patients must have at least one bi-dimensionally measurable lesion (&gt;1.5 cm in its&#xD;
             largest dimension by CT scan). Patients without such a target lesion can be accepted&#xD;
             on an individual basis if histological organ involvement can be evaluated for response&#xD;
             e.g. involvement of the skin or the gastrointestinal tract.&#xD;
&#xD;
         11. Women of childbearing potential must:&#xD;
&#xD;
               -  have a negative serum pregnancy test at screening and before Betalutin injection&#xD;
&#xD;
               -  understand that the study medication is expected to have teratogenic risk&#xD;
&#xD;
               -  agree to use, and be able to comply with, highly effective method of birth&#xD;
                  control with a Pearl-Index ≤ 1%. Contraception is required without interruption,&#xD;
                  4 weeks before starting study drug, throughout study drug therapy and for 12&#xD;
                  months after end of study drug therapy, even if she has amenorrhoea.&#xD;
&#xD;
         12. Male subjects must agree to use condoms during intercourse throughout study drug&#xD;
             therapy and the following 12 months.&#xD;
&#xD;
         13. Patients previously treated with native rituximab are eligible.&#xD;
&#xD;
         14. The patient is willing and able to comply with the protocol, and agrees to return to&#xD;
             the hospital for follow-up visits and examination.&#xD;
&#xD;
         15. The patient has been fully informed about the study and has signed the informed&#xD;
             consent form.&#xD;
&#xD;
         16. Negative HAMA test.&#xD;
&#xD;
         17. CD37 positive, re-biopsy or test on existing tumour material if not known&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Medical contraindications, including uncontrolled infection, severe cardiac,&#xD;
             pulmonary, neurologic, psychiatric or metabolic disease, steroid requiring&#xD;
             asthma/allergy, known HIV positive.&#xD;
&#xD;
          2. Laboratory values during screening :&#xD;
&#xD;
               -  Absolute Neutrophil Counts (ANC) ≤ 1.5 x 109 /l&#xD;
&#xD;
               -  Platelet count ≤ 150 x 109 /l&#xD;
&#xD;
               -  Total bilirubin ≥ 30 mmol/l&#xD;
&#xD;
               -  ALP and ALAT ≥ 4x normal level&#xD;
&#xD;
               -  GFR &lt; 60 ml/min/1.73 m2 as measured by the CKD-EPI method.&#xD;
&#xD;
          3. Known or suspected CNS involvement of lymphoma&#xD;
&#xD;
          4. Previous total body irradiation, or irradiation of &gt; 25% of the patient's bone marrow.&#xD;
&#xD;
          5. Chemotherapy, immunotherapy or another investigational drug received within the last 4&#xD;
             weeks prior to the patient entering screening.&#xD;
&#xD;
          6. Earlier treatment with radioimmunotherapy.&#xD;
&#xD;
          7. Exposure to another CD37 targeting drug.&#xD;
&#xD;
          8. Concurrent participation in another therapeutic treatment trial.&#xD;
&#xD;
          9. Previous hematopoietic stem cell transplantation (autologous and allogenic).&#xD;
&#xD;
         10. Pregnant or lactating women.&#xD;
&#xD;
         11. Transformed or potentially transformed NHL from indolent to aggressive&#xD;
&#xD;
         12. Receipt of live, attenuated vaccine within 30 days prior to enrolment&#xD;
&#xD;
         13. Test positive for hepatitis B (HBsAg and anti-HBc)&#xD;
&#xD;
         14. A known hypersensitivity to rituximab, HH1, Betalutin or murine proteins or any&#xD;
             excipient used in rituximab, HH1 or Betalutin&#xD;
&#xD;
         15. Malignant disease, other than that being treated in this study. Exceptions include:&#xD;
             malignancies that were treated curatively and have not recurred within 3 years prior&#xD;
             to study entry; completely resected basal cell and squamous cell skin cancers;&#xD;
             completely resected carcinoma in situ of any type.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Buck, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wuerzburg University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsklinikum Würzburg</name>
      <address>
        <city>Würzburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Dahle J, Repetto-Llamazares AH, Mollatt CS, Melhus KB, Bruland OS, Kolstad A, Larsen RH. Evaluating antigen targeting and anti-tumor activity of a new anti-CD37 radioimmunoconjugate against non-Hodgkin's lymphoma. Anticancer Res. 2013 Jan;33(1):85-95.</citation>
    <PMID>23267131</PMID>
  </reference>
  <reference>
    <citation>Repetto-Llamazares AH, Larsen RH, Mollatt C, Lassmann M, Dahle J. Biodistribution and dosimetry of (177)Lu-tetulomab, a new radioimmunoconjugate for treatment of non-Hodgkin lymphoma. Curr Radiopharm. 2013 Mar;6(1):20-7.</citation>
    <PMID>23256748</PMID>
  </reference>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>December 22, 2015</study_first_submitted>
  <study_first_submitted_qc>January 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2016</study_first_posted>
  <last_update_submitted>January 8, 2019</last_update_submitted>
  <last_update_submitted_qc>January 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Radioimmunotherapy</keyword>
  <keyword>Lu-177</keyword>
  <keyword>Phase I study</keyword>
  <keyword>Betalutin</keyword>
  <keyword>ARC</keyword>
  <keyword>Antibody Radionuclide Conjugate</keyword>
  <keyword>HH1</keyword>
  <keyword>Rituximab</keyword>
  <keyword>177Lu-DOTA-HH1</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Lymphoma Non-Hodgkin</keyword>
  <keyword>Immune System Diseases</keyword>
  <keyword>Follicular Lymphoma</keyword>
  <keyword>Marginal Zone Lymphoma</keyword>
  <keyword>Lymphoplasmacytoid</keyword>
  <keyword>Lymphatic Diseases</keyword>
  <keyword>Lymphoproliferative Disorders</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>Neoplasms by Histological Type</keyword>
  <keyword>Small Lymphocytic Lymphoma</keyword>
  <keyword>Classical Mantle Cell Lymphoma</keyword>
  <keyword>Lilotomab</keyword>
  <keyword>Lutetium (177Lu) lilotomab satetraxetan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

